Chemours Co (CC) stock

CCNYSEChemicals & Allied ProductsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$13.35−0.37 (-2.70%)

Close on Nov 12, 2026Market cap $2.01BP/E –Yield 3.84%

Earnings

Chemours's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 18, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

$1.50B

Adjusted EPS, Q3 FY2026

$0.21

$0.20 a year earlier

Latest guidance

Issued

Nov 2, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Chemours's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 18, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Nov 2, 2026after the close	$1.50B	–	$1.29	$0.21	Release
Q2 FY2026ended Jun 30, 2026	Aug 4, 2026after the close	$1.59B	–	-$1.81	$0.42	Release
Q1 FY2026ended Mar 31, 2026	May 5, 2026after the close	$1.38B	–	-$0.19	$0.05	Release
Q4 FY2025ended Dec 31, 2025	Feb 19, 2026after the close	$1.33B	–	-$0.31	$0.05	Release
Q3 FY2025ended Sep 30, 2025	Nov 6, 2025after the close	–	–	$0.40	$0.20	Release
Q2 FY2025ended Jun 30, 2025	Aug 5, 2025after the close	–	–	-$2.54	$0.58	Release
Q1 FY2025ended Mar 31, 2025	May 6, 2025after the close	–	–	–	–	Release
Q4 FY2024ended Dec 31, 2024	Feb 18, 2025before the open	–	–	-$0.05	$0.11	Release
Q3 FY2024ended Sep 30, 2024	Nov 4, 2024before the open	–	–	-$0.18	$0.40	Release
Q2 FY2024ended Jun 30, 2024	Aug 1, 2024after the close	$1.50B	-6.3%	$0.46	$0.38	Release
Q1 FY2024ended Mar 31, 2024	Apr 30, 2024after the close	$1.40B	-6.7%	$0.34	$0.32	Release
Q4 FY2023ended Dec 31, 2023	Mar 28, 2024after the close	$1.40B	+7.7%	-$0.12	$0.31	Release
Q3 FY2023ended Sep 30, 2023	Oct 26, 2023after the close	$1.50B	-16.7%	$0.13	$0.63	Release
Q2 FY2023ended Jun 30, 2023	Jul 28, 2023after the close	$1.60B	-15.8%	-$2.52	$1.10	Release
Q1 FY2023ended Mar 31, 2023	Apr 27, 2023after the close	$1.50B	-16.7%	$0.96	$0.98	Release
Q4 FY2022ended Dec 31, 2022	Feb 9, 2023after the close	$1.30B	-18.8%	-$0.65	$0.00	Release
Q3 FY2022ended Sep 30, 2022	Oct 25, 2022after the close	$1.80B	+5.9%	$1.52	$1.24	Release
Q2 FY2022ended Jun 30, 2022	Jul 28, 2022after the close	$1.90B	–	$1.26	$1.89	Release
Q1 FY2022ended Mar 31, 2022	May 2, 2022after the close	$1.80B	–	$1.43	$1.46	Release
Q4 FY2021ended Dec 31, 2021	Feb 10, 2022after the close	$1.60B	–	$1.40	$0.81	Release
Q3 FY2021ended Sep 30, 2021	Nov 4, 2021after the close	$1.70B	–	$1.27	$1.27	Release
Q2 FY2021ended Jun 30, 2021	Jul 29, 2021after the close	–	–	–	–	Release
Q1 FY2021ended Mar 31, 2021	May 3, 2021after the close	–	–	–	–	Release
Q4 FY2020ended Dec 31, 2020	Feb 11, 2021after the close	–	–	–	–	Release
Q3 FY2020ended Sep 30, 2020	Nov 3, 2020after the close	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Chemours's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
consolidated Net Sales	Q4 FY2026	+5% – +10%	–	New	Nov 2, 2026
consolidated Adjusted EBITDAnon-GAAP	Q4 FY2026	$160.00M – $185.00M	–	New	Nov 2, 2026
capital expenditures	Q4 FY2026	$75.00M – $85.00M	–	New	Nov 2, 2026
Corporate Expenses	Q4 FY2026	$40.00M – $45.00M	–	New	Nov 2, 2026
Net Sales	FY2026	+2%	–	New	Nov 2, 2026
Net Sales	FY2026	+1% – +5%	+3% – +5%	Lowered	Aug 4, 2026
Adjusted EBITDAnon-GAAP	FY2026	$775.00M – $800.00M	–	New	Nov 2, 2026
Adjusted EBITDAnon-GAAP	FY2026	$775.00M – $825.00M	$800.00M – $900.00M	Lowered	Aug 4, 2026
Free Cash Flowsnon-GAAP	FY2026	$195.00M – $245.00M	$170.00M – $240.00M	Raised	Aug 4, 2026
Capital expenditures	FY2026	$250.00M – $280.00M	$275.00M – $325.00M	Lowered	Aug 4, 2026
Adjusted Net Incomenon-GAAP	FY2026	$120.00M – $145.00M	$130.00M – $180.00M	Raised	Aug 4, 2026
Cash flows provided by (used for) operating activitiesGAAP	FY2026	$445.00M – $565.00M	–	Raised	May 5, 2026
Free Cash Flow Conversionnon-GAAP	FY2026	25% – 30%	21% – 27%	Raised	Aug 4, 2026
Free Cash Flow Conversionnon-GAAP	FY2026	$25.00M	–	Lowered	Aug 4, 2026
Net income attributable to ChemoursGAAP	FY2026	$165.00M – $225.00M	$165.00M – $225.00M	Lowered	May 5, 2026
net leverage rationon-GAAP	FY2026	3.8	3.8	Reaffirmed	Aug 4, 2026
Net loss attributable to ChemoursGAAP	FY2026	-$255.00M – -$230.00M	–	Lowered	Aug 4, 2026
overall Free Cash Flow Conversionnon-GAAP	FY2026	20%	–	Lowered	May 5, 2026
sales CAGR	FY2027	+5%	–	New	Nov 4, 2024
run-rate cost savingsnon-GAAP	FY2027	$250.00M	–	New	Nov 4, 2024

Guidance vs results

The last range Chemours gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
Q2 FY2024	Revenue growth	+15%	-6.25%	Below range

Guidance history

Every forecast Chemours put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 2, 2026	capital expenditures	Q4 FY2026	$75.00M – $85.00M	New
Nov 2, 2026	consolidated Adjusted EBITDA	Q4 FY2026	$160.00M – $185.00M	New
Nov 2, 2026	Adjusted EBITDA	FY2026	$775.00M – $800.00M	New
Nov 2, 2026	Corporate Expenses	Q4 FY2026	$40.00M – $45.00M	New
Nov 2, 2026	consolidated Net Sales	Q4 FY2026	+5% – +10%	New
Nov 2, 2026	Net Sales	FY2026	+2%	New
Aug 4, 2026	Capital expenditures	FY2026	$250.00M – $280.00M	Lowered
Aug 4, 2026	capital expenditures	Q3 FY2026	$65.00M	New
Aug 4, 2026	Adjusted EBITDA	FY2026	$775.00M – $825.00M	Lowered
Aug 4, 2026	Adjusted EBITDA	Q3 FY2026	$125.00M – $140.00M	New
Aug 4, 2026	Adjusted EBITDA	Q3 FY2026	$70.00M – $80.00M	Lowered
Aug 4, 2026	Adjusted EBITDA	Q3 FY2026	$20.00M – $30.00M	Lowered
Aug 4, 2026	Free Cash Flows	FY2026	$195.00M – $245.00M	Raised
Aug 4, 2026	Free Cash Flows	Q3 FY2026	$50.00M	New
Aug 4, 2026	net leverage ratio	FY2026	3.8	Reaffirmed
Aug 4, 2026	Free Cash Flow Conversion	FY2026	25% – 30%	Raised
Aug 4, 2026	Net loss attributable to Chemours	FY2026	-$255.00M – -$230.00M	Lowered
Aug 4, 2026	Free Cash Flow Conversion	FY2026	$25.00M	Lowered
Aug 4, 2026	Adjusted Net Income	FY2026	$120.00M – $145.00M	Raised
Aug 4, 2026	Corporate Expenses	Q3 FY2026	$40.00M – $45.00M	New
Aug 4, 2026	Net Sales	FY2026	+1% – +5%	Lowered
May 5, 2026	Capital expenditures	FY2026	$275.00M – $325.00M	Reaffirmed
May 5, 2026	capital expenditures	Q2 FY2026	$50.00M	New
May 5, 2026	Adjusted EBITDA	FY2026	$800.00M – $900.00M	Reaffirmed
May 5, 2026	consolidated Adjusted EBITDA	Q2 FY2026	$220.00M – $250.00M	New
May 5, 2026	Free Cash Flows	FY2026	$170.00M – $240.00M	Lowered
May 5, 2026	Free Cash Flows	Q2 FY2026	$100.00M	New
May 5, 2026	net leverage ratio	FY2026	3.8	New
May 5, 2026	overall Free Cash Flow Conversion	FY2026	20%	Lowered
May 5, 2026	Free Cash Flow Conversion	FY2026	21% – 27%	Raised
May 5, 2026	Cash flows provided by (used for) operating activities	FY2026	$445.00M – $565.00M	Raised
May 5, 2026	Net income attributable to Chemours	FY2026	$165.00M – $225.00M	Lowered
May 5, 2026	Adjusted Net Income	FY2026	$130.00M – $180.00M	Reaffirmed
May 5, 2026	Corporate Expenses	Q2 FY2026	$45.00M – $50.00M	New
May 5, 2026	Net Sales	FY2026	+3% – +5%	Reaffirmed
May 5, 2026	consolidated Net Sales	Q2 FY2026	+15% – +20%	New
Feb 19, 2026	Capital expenditures	FY2026	$275.00M – $325.00M	New
Feb 19, 2026	capital expenditures	Q1 FY2026	$50.00M	New
Feb 19, 2026	Adjusted EBITDA	FY2026	$800.00M – $900.00M	New
Feb 19, 2026	consolidated Adjusted EBITDA	Q1 FY2026	$120.00M – $150.00M	New
Feb 19, 2026	Free Cash Flows	FY2026	$200.00M – $270.00M	New
Feb 19, 2026	Free Cash Flow Conversion	FY2026	25% – 30%	New
Feb 19, 2026	Net income attributable to Chemours	FY2026	$165.00M – $225.00M	New
Feb 19, 2026	Adjusted Net Income	FY2026	$130.00M – $180.00M	New
Feb 19, 2026	Corporate Expenses	Q1 FY2026	$45.00M – $50.00M	New
Feb 19, 2026	Net Sales growth	FY2026	+3% – +5%	New
Feb 19, 2026	consolidated Net Sales	Q1 FY2026	+3% – +5%	New
Nov 6, 2025	capital expenditures	Q4 FY2025	$50.00M	New
Nov 6, 2025	Adjusted EBITDA	FY2025	$745.00M – $770.00M	New
Nov 6, 2025	consolidated Adjusted EBITDA	Q4 FY2025	$130.00M – $160.00M	New
Nov 6, 2025	Net loss attributable to Chemours	FY2025	-$335.00M – -$318.00M	New
Nov 6, 2025	Adjusted Net Income	FY2025	$127.00M – $144.00M	New
Nov 6, 2025	Free Cash Flow Conversion	Q4 FY2025	50% – 70%	New
Nov 6, 2025	Corporate Expenses	Q4 FY2025	$40.00M – $45.00M	New
Nov 6, 2025	consolidated Net Sales	Q4 FY2025	-15% – -10%	New
Aug 5, 2025	capital expenditures	Q3 FY2025	$50.00M	New
Aug 5, 2025	capital expenditures	FY2025	$250.00M	Narrowed
Aug 5, 2025	consolidated Adjusted EBITDA	Q3 FY2025	$175.00M – $195.00M	New
Aug 5, 2025	Adjusted EBITDA	FY2025	$775.00M – $825.00M	Lowered
Aug 5, 2025	Free Cash Flow Conversion	Q3 FY2025	60% – 80%	New
Aug 5, 2025	Net loss attributable to Chemours	FY2025	-$336.00M – -$300.00M	Lowered
Aug 5, 2025	Adjusted Net Income	FY2025	$156.00M – $192.00M	Lowered
Aug 5, 2025	consolidated Net Sales	Q3 FY2025	-6% – -4%	New
Aug 5, 2025	Net Sales	FY2025	$5.90B – $6.00B	New
May 6, 2025	capital expenditures	Q2 FY2025	$50.00M	New
May 6, 2025	capital expenditures	FY2025	$225.00M – $275.00M	Lowered
May 6, 2025	consolidated Adjusted EBITDA	Q2 FY2025	+40% – +45%	New
May 6, 2025	Adjusted EBITDA	FY2025	$825.00M – $950.00M	Lowered
May 6, 2025	free cash flows conversion	FY2025	60% – 80%	New
Feb 18, 2025	capital expenditures	Q1 FY2025	$80.00M	New
Feb 18, 2025	Capital expenditures	FY2025	$250.00M – $300.00M	New
Feb 18, 2025	Adjusted EBITDA	FY2025	$825.00M – $975.00M	New
Feb 18, 2025	Net income attributable to Chemours	FY2025	$200.00M – $315.00M	New
Feb 18, 2025	Adjusted Net Income	FY2025	$200.00M – $315.00M	New
Nov 4, 2024	total capex	Q4 FY2024	$100.00M	New
Nov 4, 2024	run-rate cost savings	FY2027	$250.00M	New
Nov 4, 2024	sales CAGR	FY2027	+5%	New
Apr 30, 2024	capital expenditures	Q2 FY2024	$80.00M	New
Apr 30, 2024	consolidated Adjusted EBITDA	Q2 FY2024	+15%	New
Apr 30, 2024	consolidated Net Sales	Q2 FY2024	+15%	New
Mar 27, 2024	capital expenditures	Q1 FY2024	$100.00M	New
Mar 27, 2024	consolidated Adjusted EBITDA	Q1 FY2024	-10%	New
Mar 27, 2024	Operating Cash Flow	Q1 FY2024	-$400.00M	New
Oct 26, 2023	capital expenditures	FY2023	$400.00M	Reaffirmed
Oct 26, 2023	Adjusted EBITDA	FY2023	$1.03B – $1.08B	Lowered
Oct 26, 2023	Adjusted Free Cash Flow	FY2023	$225.00M	Lowered
Jul 28, 2023	capital expenditures	FY2023	$400.00M	Reaffirmed
Jul 28, 2023	Adjusted EBITDA	FY2023	$1.10B – $1.18B	Lowered
Jul 28, 2023	Free Cash Flow	FY2023	$325.00M	Lowered
Apr 27, 2023	capital expenditures	FY2023	$400.00M	Reaffirmed
Apr 27, 2023	Adjusted EBITDA	FY2023	$1.20B – $1.30B	Reaffirmed
Apr 27, 2023	Free Cash Flow	FY2023	$350.00M	Reaffirmed
Feb 9, 2023	capital expenditures	FY2023	$400.00M	New
Feb 9, 2023	Adjusted EBITDA	FY2023	$1.20B – $1.30B	New
Feb 9, 2023	Adjusted EPS	FY2023	$3.80 – $4.29	New
Feb 9, 2023	Free Cash Flow	FY2023	$350.00M	New
Oct 25, 2022	Adjusted EBITDA	FY2022	$1.40B – $1.45B	Lowered
Oct 25, 2022	Free Cash Flow	FY2022	$575.00M	Lowered
Jul 28, 2022	Adjusted EBITDA	FY2022	$1.48B – $1.58B	Reaffirmed
Jul 28, 2022	Free Cash Flow	FY2022	$600.00M	Raised
May 2, 2022	Adjusted EBITDA	FY2022	$1.48B – $1.58B	Raised
May 2, 2022	Free Cash Flow	FY2022	$550.00M	Raised
Feb 10, 2022	capital expenditures	FY2022	$400.00M	New
Feb 10, 2022	Adjusted EBITDA	FY2022	$1.30B – $1.43B	New
Feb 10, 2022	Adjusted EPS	FY2022	$4.07 – $4.70	New
Feb 10, 2022	Free Cash Flow	FY2022	$500.00M	New
Nov 4, 2021	Capex	FY2021	$325.00M	New
Nov 4, 2021	Adjusted EBITDA	FY2021	$1.30B – $1.34B	New
Nov 4, 2021	Adjusted EPS	FY2021	$3.93 – $4.13	New
Nov 4, 2021	Free Cash Flow	FY2021	$500.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.